Zemaira Market Report 2026

Zemaira Market Overview

• The Zemaira market growth in the historic period has been driven by increased awareness of alpha-1 antitrypsin deficiency, development of plasma fractionation technologies • Market expansion is supported by increasing investments in rare disease treatments, growing demand for long-term respiratory management • Growth Driver: Rising Prevalence Of Lung Diseases Fuels Growth The Market • Market Trend: Innovative Product Developments Enhance Convenience And Adherence In The Market • North America was the largest region in 2025.

What Is Covered Under Zemaira Market?

Zemaira is an intravenous alpha1-proteinase inhibitor used as chronic augmentation therapy for adults with alpha 1-antitrypsin deficiency and emphysema, increasing functional A1-PI levels in the blood to help protect lung tissue and slow disease progression, thereby improving overall respiratory function and quality of life for affected individuals. The main indications of zemaira are alpha-1 antitrypsin deficiency, pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and others. Alpha-1 antitrypsin deficiency is an inherited condition that leads to reduced levels of alpha-1 antitrypsin, a protein essential for protecting the lungs and liver from harm. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and used by several end users, including adults and geriatric patients.

What Is The Zemaira Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease treatments, growing demand for long-term respiratory management, expansion of specialty pharmacy distribution, rising focus on personalized respiratory care, advancements in plasma protein therapeutics. Major trends in the forecast period include expansion of augmentation therapy adoption, increasing focus on rare respiratory disorders, growing demand for plasma-derived therapies, enhanced monitoring of long-term respiratory outcomes, rising emphasis on early diagnosis.

Global Zemaira Market Segmentation

1) By Indication: Alpha-1 Antitrypsin Deficiency, Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Other Respiratory Disorders 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 3) By End-User: Adults, Geriatric Patients

What Are The Drivers Of The Zemaira Market?

The increasing prevalence of lung diseases is expected to propel the growth of the zemaira market going forward. Lung diseases encompass various conditions that impair the lungs' normal function, such as asthma, pneumonia, chronic obstructive pulmonary disease (COPD), and lung cancer. The prevalence of lung diseases is primarily driven by factors such as rising tobacco use, exposure to air pollution, occupational hazards, and a higher incidence of respiratory infections. Zemaira is an intravenous infusion of human alpha-1 antitrypsin (AAT) that restores deficient AAT levels in patients, helping to prevent additional lung damage, enhance lung function, and lower the risk of respiratory complications linked to the condition. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, 2.8 million people (11%) were living with asthma in 2022, contributing to 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023, with 467 deaths (1.8 per 100,000 population) recorded in 2022, accounting for 0.2% of all deaths. Therefore, the increasing prevalence of lung diseases is driving the growth of the zemaira industry. A growing number of clinical trials is expected to propel the growth of the Zemaira market going forward. Clinical trials refer to carefully designed research studies conducted in humans to evaluate the safety, efficacy, and effectiveness of new medical treatments, drugs, devices, or interventions. The increasing prevalence of chronic and complex diseases is driving the growth of clinical trials, as more research is needed to develop effective treatments and therapies. Clinical trials support Zemaira by rigorously evaluating its safety and efficacy, providing critical evidence that informs regulatory approvals and guides optimal patient use. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the growing number of clinical trials is driving the growth of the Zemaira industry.

Key Players In The Global Zemaira Market

Major companies operating in the zemaira market are CSL Behring LLC

Global Zemaira Market Trends and Insights

The key trend in the zemaira market is the introduction of advancements, such as larger vial sizes, designed to enhance convenience and reduce treatment frequency. These larger vial sizes optimize the dosing regimen by allowing healthcare professionals to reconstitute fewer vials per dose, simplifying the treatment process and improving adherence for patients who often struggle with the burden of frequent infusions. For instance, in January 2024, CSL Behring, a US-based biotechnology company, demonstrated its continued commitment to the Alpha-1 community with the introduction of 4- and 5-gram vials of ZEMAIRA (Alpha1-Proteinase Inhibitor [Human]). This new offering builds on the previously available 1-gram vials and aims to simplify the preparation process for patients. By reducing the number of vials needed per treatment, CSL Behring strives to minimize waste, supporting its sustainability goals, while ZEMAIRA continues to play a vital role in managing Alpha-1 Antitrypsin Deficiency by maintaining adequate protein levels in patients' blood.

Regional Insights

North America was the largest region in the zemaira market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zemaira Market?

The zemaira market consists of sales of lyophilized powder for injection and sterile solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zemaira Market Report 2026?

The zemaira market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zemaira industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.